Normocytic anemia
MONDO:0004139Anemia in which the red blood cell volume is normal.
Also known as: anaemia normocytic, anemia normocytic, normocytic Anaemia, normocytic Anemia
203 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
Disease control CompletedThis phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilir…
Phase: PHASE2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for rare blood disorder: ravulizumab trial shows promise in china
Disease control CompletedThis completed Phase 3 trial tested ravulizumab in 18 adults in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study measured changes in LDH, a marker of red blood cell breakdown, to see if the drug could control the…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for PNH patients: Long-Term drug safety confirmed
Disease control CompletedThis study tested the long-term safety of a drug called pegcetacoplan in people with PNH, a rare blood disease that destroys red blood cells. All 137 participants had already completed a prior pegcetacoplan study and continued treatment. The main goal was to track side effects ov…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for PNH patients in china: eculizumab shows promise
Disease control CompletedThis study tested eculizumab in 25 adults with PNH in China who had not previously taken complement inhibitors. Participants received infusions over 62 weeks. The main goal was to see if the drug reduced LDH levels, a marker of disease activity. Results showed a decrease in LDH, …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise in early trial for rare blood disorder
Disease control CompletedThis early study tested an experimental drug called OMS906 (zaltenibart) in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where red blood cells break apart. The main goal was to check safety and how the body handles the drug. Researchers also look…
Phase: PHASE1 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Real-World check: newer PNH drug holds up in routine care
Disease control CompletedThis study followed 120 adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from the older drug eculizumab to the newer ravulizumab. Researchers measured changes in a blood marker called LDH to see if the new drug controlled red blood cell breakdown just as well or…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a drug shorten dialysis for kids with a rare kidney disease?
Disease control CompletedThis study tested whether the drug eculizumab (Soliris) can help children with a severe kidney condition called STEC-HUS recover faster. The trial gave 100 children either eculizumab or a placebo over several weeks. The main goal was to see if the drug reduces the number of days …
Phase: PHASE3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising new drug shows hope for rare anemia patients
Disease control CompletedThis study tested a drug called mitapivat (AG-348) in 52 adults with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The goal was to see if different doses of the drug are safe and help control the dis…
Phase: PHASE2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Acid lock could fight blood infections in cancer patients
Disease control CompletedThis study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New transplant cocktail aims to cut complications in bone marrow failure
Disease control CompletedThis phase 2 trial tested a combination of treosulfan, fludarabine, and rabbit antithymocyte globulin before a bone marrow transplant in 40 people with bone marrow failure diseases like Diamond-Blackfan anemia and Shwachman-Diamond syndrome. The goal was to see if this conditioni…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental cell therapy offers hope for Hard-to-Treat blood disorder
Disease control CompletedThis early-phase study tested a new cell therapy called YTS109 in 7 people with a severe type of autoimmune anemia that did not get better after at least 3 other treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the dise…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill shows promise for PNH patients still anemic on standard therapy
Disease control CompletedThis study tested a new tablet called HSK39297 in 36 adults with paroxysmal nocturnal hemoglobinuria (PNH) who still had anemia despite stable treatment with anti-C5 antibodies. The goal was to see if the pill could raise hemoglobin levels and reduce the need for blood transfusio…
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New PNH pill matches standard infusion therapy in trial
Disease control CompletedThis study tested an oral medication called iptacopan in 52 adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who were already stable on standard infusion treatments. Participants switched from their usual therapy to iptacopan pills taken twice daily. The main goal was to see…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New oral drug HRS-5965 shows promise for tough PNH anemia cases
Disease control CompletedThis phase 3 trial tested a new drug called HRS-5965 in 39 adults with paroxysmal nocturnal hemoglobinuria (PNH) who remained anemic even after standard anti-C5 antibody treatment. The study aimed to see if the drug could raise hemoglobin levels without needing blood transfusions…
Phase: PHASE3 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill shows promise for rare blood disorder in phase 3 trial
Disease control CompletedThis study tested a new pill called HSK39297 against a standard infusion drug (eculizumab) in 73 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. Participants had not received prior complement inhibitor treatment. The mai…
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill could cut blood transfusions for blood disorders
Disease control CompletedThis Phase 2 study tested an experimental drug called etavopivat in 53 people with thalassemia or sickle cell disease. The goal was to see if the pill could safely reduce the number of red blood cell transfusions needed and raise hemoglobin levels. Participants took 400 mg of eta…
Phase: PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for rare blood disorder: Long-Term drug study shows promise
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug mitapivat in 90 adults with pyruvate kinase deficiency, a rare genetic blood disorder that causes red blood cells to break down too quickly. Participants had already completed earlier studies of mitapivat and…
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug shows promise for rare blood disorder
Disease control CompletedThis study tested a drug called pegcetacoplan in 24 adults with cold agglutinin disease, a rare condition where the immune system destroys red blood cells. Participants received either the drug or a placebo twice a week for 24 weeks. The goal was to see if the drug could raise he…
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for PNH patients: experimental drug OMS906 shows promise in early trial
Disease control CompletedThis study tested a new drug called OMS906 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who were not getting enough benefit from the standard treatment ravulizumab. The goal was to see if OMS906 is safe and can improve hemoglobin levels. Participants received OMS90…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Daily vitamin d may slash lung risks in kids with sickle cell disease
Disease control CompletedThis study tested whether taking vitamin D every day could reduce lung complications in children and teens with sickle cell disease. Lung problems like infections, asthma attacks, and acute chest syndrome are major causes of illness and death in this condition. Researchers gave d…
Phase: PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug BIVV020 tested for rare blood disorder
Disease control CompletedThis early-stage trial tested a single dose of the drug BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system mistakenly attacks red blood cells. The main goal was to see if the drug is safe and tolerable. Researchers also looked at how it af…
Phase: PHASE1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Japanese CAD patients get continued access to experimental drug sutimlimab
Disease control CompletedThis study gave sutimlimab to 7 adults in Japan with cold agglutinin disease (CAD) who had already completed earlier trials and still needed treatment. The goal was to monitor safety and side effects over time until the drug became commercially available. It is a small, open-labe…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:23 UTC
-
New pill could rival standard infusion for rare blood disorder
Disease control CompletedThis Phase 3 study tested a new oral medication, HRS-5965, against the standard infusion eculizumab in 76 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The main goal was to see if HRS-5965 could raise hemoglobin levels to normal without needing blo…
Phase: PHASE3 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:17 UTC
-
Gene therapy offers hope for rare blood disorder
Disease control CompletedThis phase 1 trial tested a gene therapy called RP-L301 in 4 people with pyruvate kinase deficiency, a rare inherited blood disorder that causes severe anemia and often requires frequent blood transfusions. The treatment uses the patient's own blood stem cells, which are modified…
Phase: PHASE1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:53 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Monthly chat group may ease isolation for young transplant patients
Symptom relief CompletedThis study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Asthma drug may ease cancer treatment side effects
Symptom relief CompletedThis study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
No treatment, just observation: large study looks at PNH blood cells
Knowledge-focused CompletedThis completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to unlock the secrets of Children's rare blood diseases
Knowledge-focused CompletedThis study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better un…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Blood cancer enzyme deficiency explored in new study
Knowledge-focused CompletedThis study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Anemia in kids may be tied to bigger hearts, study finds
Knowledge-focused CompletedThis study explored whether low hemoglobin (anemia) is linked to an enlarged heart (cardiomegaly) in children up to 18 years old. Researchers used chest X-rays and echocardiograms to check for heart enlargement in 56 anemic children. The goal was to better understand how anemia a…
Sponsor: Universitas Sumatera Utara • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists probe immune cells behind rare anemia
Knowledge-focused CompletedThis study looked at how certain immune cells, called T cells, behave in people with autoimmune hemolytic anemia, a condition where the body attacks its own red blood cells. Researchers compared blood samples from 27 patients and healthy volunteers to understand the disease bette…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
AI and MRI join forces to speed up cancer radiation planning
Knowledge-focused CompletedThis completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…
Phase: NA • Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Massive PNH registry reveals Real-World treatment safety
Knowledge-focused CompletedThis study collected health information from over 6,000 people with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare blood disorder. The goal was to track the safety of two medications, Soliris and Ultomiris, and to understand how PNH changes over time. Participants were followe…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Massive study reveals hidden struggles of stem cell survivors
Knowledge-focused CompletedThis study looked at over 1,200 people in Denmark who had a stem cell transplant for blood diseases, some as far back as 1970. Researchers used detailed surveys to measure late effects and quality of life. The goal is to find out what medical and personal factors help survivors f…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New study tracks PNH patients in china to uncover disease patterns
Knowledge-focused CompletedThis completed study followed 724 people in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers aimed to better understand how the disease progresses and how patients respond to different treatments, including the newly available drug eculizum…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Warm-Up secrets revealed: study tests best way to boost soccer skills
Knowledge-focused CompletedThis study looked at how different stages of muscle warm-up affect knee joint awareness, jumping power, agility, and balance in 25 professional youth soccer players under 18. Players were tested during rest, after warm-up, and when fatigued. The goal was to understand how warm-up…
Phase: NA • Sponsor: Necmettin Erbakan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
First human test of LP-005 drug completed in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested a new drug, LP-005, in 68 healthy adults aged 18 to 50. The main goal was to check if the drug is safe and how the body handles it. This information will help design future studies for people with a rare blood disorder called PNH.
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Rare cholesterol disorder linked to hidden eye risk
Knowledge-focused CompletedThis study looked at 10 people with rare genetic conditions that cause very low cholesterol and trouble absorbing vitamins. Researchers measured a protective pigment in the eye called macular pigment, which may be low in these patients and could explain why some still develop vis…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Lung scans reveal hidden patterns in blood disease patients
Knowledge-focused CompletedThis completed study examined lung CT scans from 148 adults with blood diseases to identify common patterns of lung involvement. Researchers tracked how often certain radiological features appeared and counted complications. The goal was to better understand the range of lung iss…
Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New registry aims to unravel severe blood disorders in youth
Knowledge-focused CompletedThis completed registry study followed 80 children and young adults with severe immune cytopenias, including immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome. Researchers observed participants over up to 4 years to improve diagnosis and track the disease c…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Which Warm-Up boosts young Goalkeepers' performance best?
Knowledge-focused CompletedThis study tested how different warm-up protocols affect flexibility, explosive power, and balance in 15 adolescent male football goalkeepers. Participants performed aerobic running, static stretching, dynamic stretching, or movement preparation before tests. The goal is to ident…
Phase: NA • Sponsor: Uşak University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:02 UTC